All eyes on oral MS drug Tecfidera as Biogen issues results, guidance
This article was originally published in Scrip
Executive Summary
As Biogen Idec reported a 9% year-over-year increase in annual revenue to $5.5 billion in 2012, all eyes were focused on sales of the oral multiple sclerosis (MS) drug Tecfidera (formerly BG-12) as the company and its investors eagerly await a US FDA approval decision within the next two months.